Patient Access to Targeted Therapies – Changes in Companion Diagnostic Reimbursement and Access to State-of-the-Art Therapies

Patient Access to Targeted Therapies Updated VOL 1, NO 1

Molecular diagnostics are at the center of personalized healthcare. In July 2012, a rapid molecular test for Kirsten RNA associated rat sarcoma 2 virus gene (KRAS) mutations—the therascreen KRAS RGQ PCR Kit (therascreen KRAS test)—was the first to receive approval from the US Food and Drug Administration (FDA) as a [ Read More ]